Emergent Biosolutions
EBS
122 hedge funds and large institutions have $91.6M invested in Emergent Biosolutions in 2024 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 29 increasing their positions, 47 reducing their positions, and 33 closing their positions.
112% more call options, than puts
Call options by funds: $1.12M | Put options by funds: $528K
9% less funds holding
Funds holding: 134 → 122 (-12)
9% less capital invested
Capital invested by funds: $101M → $91.6M (-$9.5M)
12.02% less ownership
Funds ownership: 81.22% → 69.21% (-12%)
36% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 33
38% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$4.3M |
| 2 |
Charles Schwab
San Francisco,
California
|
+$2.88M |
| 3 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$1.75M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$1.35M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.27M |
| 2 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
-$3.95M |
| 3 |
Millennium Management
New York
|
-$2.71M |
| 4 |
Morgan Stanley
New York
|
-$2.65M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$2.5M |
EBS Hedge Fund Activity: Q1 2024 in Review
122 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q1 2024, worth a combined $91.6M — down 9.4% from $101M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of EBS and 21 opened new positions — a net loss of 12 holders — while 47 trimmed existing stakes and 29 added.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $4.3M. The largest seller was BlackRock, cutting an estimated $5.27M.
- 122 institutional investors held Emergent Biosolutions (EBS) as of Q1 2024, down from 134 in Q4 2023.
- Funds reported $91.6M of Emergent Biosolutions stock for Q1 2024, down 9.4% quarter-over-quarter.
- 21 funds opened new Emergent Biosolutions positions in Q1 2024 and 33 closed out, a net change of -12 holders.
- The largest Emergent Biosolutions buyer in Q1 2024 was Avidity Partners Management, an estimated $4.3M added.
- The largest Emergent Biosolutions seller in Q1 2024 was BlackRock, an estimated $5.27M sold.
Based on aggregated 13F filings for Q1 2024.